Skip to Content

Baricitinib Approval Status

  • FDA approved: No
  • Generic name: baricitinib
  • Company: Eli Lilly and Company and Incyte Corporation
  • Treatment for: Rheumatoid Arthritis

Baricitinib is an oral selective JAK1 and JAK2 inhibitor in development for the treatment of rheumatoid arthritis.

Development Status and FDA Approval Process for baricitinib

DateArticle
Jan 19, 2016Lilly and Incyte Announce Submission of NDA to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis
Oct 14, 2015Baricitinib Demonstrates Superiority To Adalimumab In Improving Signs And Symptoms Of Rheumatoid Arthritis In Pivotal Phase 3 Study
Sep 29, 2015Baricitinib Superior To Methotrexate In Reducing Signs And Symptoms In Pivotal Phase 3 Study In Patients With Rheumatoid Arthritis
Jun 10, 2015Lilly and Incyte Unveil Detailed Data on Two Pivotal Studies of Baricitinib in Rheumatoid Arthritis
Feb 23, 2015Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3 Study
Dec  9, 2014Lilly And Incyte Announce Positive Top-Line Results From Phase 3 Trial Of Baricitinib In Moderate To Severe Rheumatoid Arthritis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide